Molecular characterization of defective antigen processing in human prostate cancer. - Wikidata - wikimedia - TriplyDB

Molecular characterization of defective antigen processing in human prostate cancer.

Molecular characterization of defective antigen processing in human prostate cancer.

http://www.wikidata.org/entity/Q36183805

about

Natural selection of tumor variants in the generation of "tumor escape" phenotypes Combined genetic and epigenetic interferences with interferon signaling expose prostate cancer cells to viral infection Progress in active specific immunotherapy of prostate cancer.Heterogeneity in expression of human leukocyte antigens and melanoma-associated antigens in advanced melanoma.The Current Status of Gene Therapy for Prostate Cancer.Novel strategies and therapeutics for the treatment of prostate carcinoma.T-cell-directed cancer vaccines: mechanisms of immune escape and immune tolerance.Secretable chaperone Grp170 enhances therapeutic activity of a novel tumor suppressor, mda-7/IL-24 T cell coinhibition in prostate cancer: new immune evasion pathways and emerging therapeutics.Sipuleucel-T for therapy of asymptomatic or minimally symptomatic, castrate-refractory prostate cancer: an update and perspective among other treatments.Antitumor efficacy of tumor-antigen-encoding recombinant poxvirus immunization in Dunning rat prostate cancer: implications for clinical genetic vaccine development.Antigen-specific tumor vaccine efficacy in vivo against prostate cancer with low class I MHC requires competent class II MHC.Association of HLA class I antigen abnormalities with disease progression and early recurrence in prostate cancer In the field: exploiting the untapped potential of immunogenic modulation by radiation in combination with immunotherapy for the treatment of cancer.T cells engineered with a T cell receptor against the prostate antigen TARP specifically kill HLA-A2+ prostate and breast cancer cells Synergizing radiation therapy and immunotherapy for curing incurable cancers. Opportunities and challenges Gene delivery and gene therapy of prostate cancer.Non-classical HLA-G antigen and its role in the cancer progression.Induction of tumor antigen-specific immunity in vivo by a novel vaccinia vector encoding safety-modified simian virus 40 T antigen.MHC class I and class II molecules are expressed in both human and mouse prostate tumor microenvironment.Sympathetic modulation of immunity: relevance to disease.Particulate matter containing environmentally persistent free radicals and adverse infant respiratory health effects: a review.Immunology and immunotherapy approaches for prostate cancer.Vaccination with agonist peptide PSA: 154-163 (155L) derived from prostate specific antigen induced CD8 T-cell response to the native peptide PSA: 154-163 but failed to induce the reactivity against tumor targets expressing PSA: a phase 2 study in p Secretion of stress protein grp170 promotes immune-mediated inhibition of murine prostate tumor.The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma.Emerging drugs for prostate cancer.Sipuleucel-T: Prototype for development of anti-tumor vaccines.Recent advances in immunotherapy for the treatment of prostate cancer.Tumor evasion from T cell surveillance.Isolated, disseminated and circulating tumour cells in prostate cancer.The cancer biology of whole-chromosome instability.Targeting epigenetic mechanisms for clinical translation: enhancing the efficacy of tumor immunotherapies.Interleukin-32 enhances cytotoxic effect of natural killer cells to cancer cells via activation of death receptor 3.Prostate stem cell antigen DNA vaccination breaks tolerance to self-antigen and inhibits prostate cancer growth.Oncolytic virus-initiated protective immunity against prostate cancer Bacillus Calmette-Guérin cell-wall skeleton enhances the killing activity of cytotoxic lymphocyte-activated human dendritic cells transduced with the prostate-specific antigen gene.Targeting epitopes in prostate-specific membrane antigen for antibody therapy of prostate cancer.Comparison of HPV DNA vaccines employing intracellular targeting strategies.Adoptive immunotherapy of prostate cancer bone lesions using redirected effector lymphocytes.

P2860

Q24551158-D3421D4C-E003-400C-A79B-C6555BB8B2B1 Q28817152-6D9C5B6B-6C41-4DF6-8FB5-AD3D44F9E072 Q33807301-4BD917C2-B093-4CE6-89F0-D4C2E945F09E Q33827463-BF028BB3-BA4B-47AF-AC67-323A0A7FA72E Q33889283-0EDBA48D-6D7F-468C-BEE1-B956A57C06A7 Q34043331-3B4E44C2-5819-4173-B3AA-6BA1B1B3352C Q34452013-0E61B0BF-D3C3-4303-AE8C-067F31D37B99 Q34514012-92436169-2E10-4A86-85F8-D76293E12451 Q34577158-AE4825AC-D961-4A49-98BB-7F41FD193DD5 Q35128716-6DB478B5-25FA-40FB-81C2-4A62D700BE26 Q36093425-CF506554-E18F-4442-AAE1-6F0D5079F7B2 Q36093442-B0CDD853-E553-4863-B0A9-E41F291ABB12 Q36184735-60C8193E-C760-4292-99A5-82400EC9A03A Q36210670-0FC3273B-83C7-4DE2-A1B8-6E8BCE1764F4 Q36300730-1403C917-F9D0-45FD-8889-3AAA052EB158 Q36326713-20C1AF67-ADB1-4341-97CB-867C8FCD77C0 Q36349678-F25B71AB-3BE4-41E4-90D5-D95A55FC2BE0 Q36421272-E631CB33-C1DE-41E6-BD6E-BFC11F7FC1DE Q36473836-F08710CF-6B91-4D2A-BE1B-23E77DD4B7F8 Q36513540-6A35FEE3-BE9A-49AE-92D2-5128ADAF3FEC Q36552147-43FC61FD-5FCD-4535-B264-52B1C84D16E8 Q36632149-07358894-9753-4A48-9F21-8309A93198B3 Q36786512-AA904F4A-3E55-4449-B4BF-9EB7304B6E89 Q37379219-300CB3A4-A0E9-45F4-8102-A3B220138A9D Q37464444-C6640DB7-2F03-431A-B92F-F57CFCE7A54C Q37518336-44694836-6473-4694-BD19-0AC5A327A253 Q37570555-0D8D43A6-0534-4805-8310-633F9A6728AA Q37829694-C632D534-3378-4732-9218-6616A2D31DD0 Q37889984-06C333FA-8B04-4803-8EFF-4AD0FB7675E9 Q37970674-F2B9F985-75C8-41F6-B14D-18B057F7DE7A Q38024987-465FC542-7833-4612-825F-ED4F23BA1442 Q38074016-FC9F7224-2642-473E-A788-BDB1080F7835 Q38159805-C96C2F41-B1AF-4627-8A37-5558BB16154F Q38469030-6C4DD944-0F3A-49E9-907D-C3DBB2FF5FDB Q39507581-8635DFBC-F579-487E-98E6-127BD6CA2AA2 Q39606073-DDDB077D-D793-4F2E-86F8-FF47D8ACDF67 Q39753779-4934B9A0-3ECD-479B-A2CD-DF87E99B37B2 Q40371330-E7FD00B0-7EAD-42C2-963B-BA8DA8FADDDC Q40529159-2024FF65-D46D-44D8-9635-4A950A077DD2 Q40619033-7B0DDFA3-2DC1-4C14-9948-B68A5ED2BADA

P2860

Molecular characterization of defective antigen processing in human prostate cancer.

http://www.wikidata.org/entity/Q36183805

description

1995 nî lūn-bûn

@nan

1995年の論文

@ja

1995年論文

@yue

1995年論文

@zh-hant

1995年論文

@zh-hk

1995年論文

@zh-mo

1995年論文

@zh-tw

1995年论文

@wuu

1995年论文

@zh

1995年论文

@zh-cn

name

Molecular characterization of defective antigen processing in human prostate cancer.

@ast

Molecular characterization of defective antigen processing in human prostate cancer.

@en

type

label

Molecular characterization of defective antigen processing in human prostate cancer.

@ast

Molecular characterization of defective antigen processing in human prostate cancer.

@en

prefLabel

Molecular characterization of defective antigen processing in human prostate cancer.

@ast

Molecular characterization of defective antigen processing in human prostate cancer.

@en

P1433

Q36183805-37DB5B7C-7E54-4770-B801-1FA04AC64618

P1476

Q36183805-0EB13BE2-DAD4-48CA-8491-35C70E58EB79

P2093

Q36183805-45CD02B5-1022-4834-BE0F-1743BB790792

Q36183805-574FB9CB-4D6E-48D0-9A89-5A6E045D0035

Q36183805-59080933-1FD0-41BA-9966-B6D28212DC67

Q36183805-A07441B3-7680-4D18-8A17-253F10D991ED

Q36183805-B8C1CF13-6F17-45CB-8CD9-C3EFBC34E24E

Q36183805-C88C3F8F-F3AC-4292-B945-910B24B2DB20

P2860

Q36183805-0FC985B9-DB73-4CD7-82C1-16E198B57B9B

Q36183805-17FDCDAF-D37D-4582-B042-EC2C441333AD

Q36183805-34342F37-2E97-4194-B557-8545200B983C

Q36183805-7334E131-5737-41D6-9012-BE835C11A765

Q36183805-87CB253E-4D0A-4875-9472-BA5D5B2AE94F

Q36183805-B1E691AE-6BC2-4745-A73A-A69349AA6A0D

Q36183805-B6ED17D7-CE57-491F-B467-DE321198C492

Q36183805-B92B559B-67D3-41A2-B7F9-946A37D0F124

Q36183805-CD0759EB-9BB2-4179-B409-E77263123730

Q36183805-D9C86E00-ADDC-4336-81E9-D2118BF30392

P304

Q36183805-1E967E27-82B1-47CC-9446-61FED60086D7

P31

Q36183805-D5A9F202-B8FB-426C-B733-20E8F8B1D42E

P356

Q36183805-B43AF80A-453F-4C70-A26C-32DA6F7D499B

P407

Q36183805-2D428CC4-5AEB-40AE-B5C4-C9D43C56700E

P433

Q36183805-DCA4F518-C295-4433-B23A-40CA7ACEDB92

P478

Q36183805-78F206ED-FC85-4467-A28D-60729DEBA473

P50

Q36183805-DFB4072B-CF4E-44B0-8CD3-D0C76FA257F2

P577

Q36183805-CD46AF0A-E25C-43E9-ACD2-50C4731D7F8F

P5875

Q36183805-AB491F3F-1375-4060-831D-1B59C6029A46

P698

Q36183805-9742FC50-290A-4B27-8EA2-C589BDF2B2FC

P932

Q36183805-C7762823-4859-40D1-BDD2-3761B8DD006B

P356

P1433

Journal of the National Cancer Institute

P1476

Molecular characterization of defective antigen processing in human prostate cancer

@en

P2093

D M Pardoll

http://www.w3.org/2001/XMLSchema#string

J C Walsh

http://www.w3.org/2001/XMLSchema#string

J W Simons

http://www.w3.org/2001/XMLSchema#string

M G Sanda

http://www.w3.org/2001/XMLSchema#string

W G Nelson

http://www.w3.org/2001/XMLSchema#string

Y Kawakami

http://www.w3.org/2001/XMLSchema#string

P2860

Identification of human cancers deficient in antigen processing

Sequences encoded in the class II region of the MHC related to the 'ABC' superfamily of transporters

A gene in the human major histocompatibility complex class II region controlling the class I antigen presentation pathway

Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity.

Murine tumor cells transduced with the gene for tumor necrosis factor-alpha. Evidence for paracrine immune effects of tumor necrosis factor against tumors

A nonimmunogenic sarcoma transduced with the cDNA for interferon gamma elicits CD8+ T cells against the wild-type tumor: correlation with antigen presentation capability.

In vivo priming of two distinct antitumor effector populations: the role of MHC class I expression

Prostate cancer kills: strategy to reduce deaths.

Immunotherapy of prostate cancer in the Dunning rat model: use of cytokine gene modified tumor vaccines.

Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4.

P304

280-285

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/JNCI/87.4.280

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

87

http://www.w3.org/2001/XMLSchema#string

P50

Nicholas P. Restifo

P577

1995-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

31003261

http://www.w3.org/2001/XMLSchema#string

P698

7707419

http://www.w3.org/2001/XMLSchema#string

P932

2104544

http://www.w3.org/2001/XMLSchema#string